Search - tctmd.com

Displaying 101 - 113 of 113

Sort: Relevancy | Date

News Conference News ACC 2012

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

Yael L. Maxwell

March 27, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Jason Kahn

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Presenter: Antonio Colombo

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Video

» Interview

ACC 2022: The FAME 3 Trial - Quality of Life After Fractional Flow Reserve-guided Stenting Compared with Coronary Bypass Surgery

April 3, 2022

Video

» Interview

ACC 2019: STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation

March 18, 2019

Advertisement

ASCERT: Long-term Survival Advantage with CABG in Multivessel Disease

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

ACC 2022: The FAME 3 Trial - Quality of Life After Fractional Flow Reserve-guided Stenting Compared with Coronary Bypass Surgery

ACC 2019: STOPDAPT-2 Trial: One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content